NCT02347891View on ClinicalTrials.gov

Belimumab in Idiopathic Inflammatory Myositis

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions

Myositis

Interventions

DRUG

Belimumab

Randomized phase: Week 0 - Week 40

DRUG

Placebo

Randomized phase: Week 0 - Week 40

Trial Locations (1)

11021

Northwell Health Divison of Rheumatology, Great Neck

Sponsors

Lead Sponsor

Northwell Health

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Northwell Health

OTHER